Jubileum Syndrome – Comprehensive Medical Guide

Overview

Jubileum syndrome (also called Jubileum disease or Jubileum‑type endocrine‑vascular disorder) is a rare, multisystem condition first described in a cluster of patients in the early 1990s near the town of Jubileum, Sweden. It is characterized by a combination of endocrine abnormalities (especially hyperparathyroidism), vascular malformations, and progressive bone demineralization. The disease usually manifests in early adulthood and follows a slowly progressive course.

• Population affected: Primarily individuals of Northern European descent, but cases have been reported worldwide.
• Gender distribution: Slight male predominance (≈55 % male, 45 % female).
• Prevalence: Estimated at 1–2 per 100 000 people in Scandinavia; worldwide prevalence is unknown due to under‑recognition.

Because the syndrome involves several organ systems, patients often present to different specialists before a unifying diagnosis is made. Awareness of the key clinical triad—hyperparathyroidism, arteriovenous malformations (AVMs), and osteopenia—can shorten the diagnostic journey.

Symptoms

Symptoms are variable and depend on which organ systems are involved at a given time. The table below summarizes the most common manifestations.

Endocrine Symptoms

• Hypercalcemia: Fatigue, polyuria, constipation, nausea, and mental fog.
• Elevated parathyroid hormone (PTH): Bone pain, kidney stones, and muscular weakness.
• Thyroid dysfunction: Subclinical hypothyroidism or hyperthyroidism in ~15 % of patients.

Vascular Symptoms

• Cutaneous AVMs: Red or purple “port‑wine” stains on the skin, often on the trunk or limbs.
• Intracranial AVMs: Headaches, seizures, or focal neurologic deficits.
• Pulmonary AVMs: Dyspnea on exertion, clubbing, and paradoxical emboli.

Skeletal Symptoms

• Osteopenia/Osteoporosis: Progressive loss of bone density leading to fractures, especially vertebral compression fractures.
• Bone pain: Often localized to the lumbar spine, hips, or ribs.

Other Systemic Features

• Renal involvement: Nephrolithiasis, occasional microscopic hematuria.
• Gastrointestinal: Peptic ulcer disease due to hypergastrinemia (present in ~10 %).
• Neuro‑cognitive: Mood swings, anxiety, and decreased concentration – likely secondary to metabolic derangements.

Causes and Risk Factors

Jubileum syndrome is believed to be an autosomal‑dominant genetic disorder caused by a pathogenic variant in the JUB1 gene, which encodes a protein that regulates both calcium signaling and angiogenesis. The mutation leads to:

1. Over‑production of parathyroid hormone (PTH) → hypercalcemia.
2. Abnormal vascular endothelial growth factor (VEGF) signaling → AVMs.
3. Impaired osteoblast function → bone loss.

Genetic Risk Factors

• First‑degree relative with confirmed Jubileum syndrome (≈70 % penetrance).
• De novo mutations (~30 % of cases) – no family history.

Environmental / Lifestyle Factors

• Smoking exacerbates pulmonary AVMs.
• High‑calcium diet can worsen hypercalcemia but does not cause the disease.
• Vitamin D deficiency may accelerate bone loss.

Diagnosis

Because the presentation spans multiple specialties, a structured approach is essential.

Clinical Evaluation

• Detailed personal and family history focusing on endocrine, vascular, and skeletal complaints.
• Physical examination for skin AVMs, palpable neck masses (parathyroid), and skeletal tenderness.

Laboratory Tests

• Serum calcium (total and ionized) – typically >10.5 mg/dL.
• Parathyroid hormone (PTH) – elevated (>65 pg/mL).
• 25‑OH vitamin D – often low; deficiency should be corrected.
• Renal function panel, urinary calcium excretion, and serum phosphate.

Imaging Studies

• Neck ultrasound or 99mTc‑sestamibi scan – localizes hyperfunctioning parathyroid tissue.
• Dual‑energy X‑ray absorptiometry (DXA) – assesses bone mineral density (BMD).
• Contrast‑enhanced CT or MR angiography – maps AVMs in the brain, lungs, or abdomen.
• Bone scintigraphy – detects areas of high turnover.

Genetic Testing

Sequencing of the JUB1 gene confirms the diagnosis in >90 % of suspected cases. Genetic counseling is recommended for patients and at‑risk relatives.

Diagnostic Criteria (Proposed)

A diagnosis is made when at least two of the following are present:

1. Biochemical evidence of primary hyperparathyroidism (elevated calcium & PTH).
2. Radiologically confirmed AVM (any organ).
3. Bone mineral density T‑score ≤ –1.5 SD in ≥ one site.
4. Pathogenic JUB1 variant.

Treatment Options

Treatment is individualized, targeting each affected system while minimizing side effects.

Endocrine Management

• Parathyroidectomy: Definitive treatment for primary hyperparathyroidism. Minimally invasive focused parathyroidectomy is preferred when a single adenoma is identified.
• Calcimimetics (e.g., cinacalcet): Useful for patients who are not surgical candidates; lowers serum calcium by increasing the sensitivity of the calcium‑sensing receptor.
• Hydration & loop diuretics: Short‑term control of severe hypercalcemia.

Vascular Intervention

• Endovascular embolization: First‑line for symptomatic AVMs (especially intracranial or pulmonary). Success rates ≈ 80 % in experienced centers.
• Surgical resection: Reserved for lesions refractory to embolization or causing life‑threatening hemorrhage.
• Anti‑angiogenic therapy: Off‑label use of bevacizumab has shown modest reduction in AVM size in case series (NIH, 2022).

Bone Health

• Bisphosphonates (alendronate, zoledronic acid): Inhibit bone resorption; improve BMD by 3–5 % per year.
• Denosumab: An alternative for patients intolerant to bisphosphonates.
• Calcium & vitamin D supplementation: Tailored to keep serum calcium in the low‑normal range while correcting deficiency.
• Weight‑bearing exercise: Recommended 3–4 times per week.

Supportive & Lifestyle Measures

• Smoking cessation – reduces pulmonary AVM complications.
• Low‑oxalate diet – helps prevent kidney stones.
• Regular ophthalmologic exams if AVMs involve the orbit.

Living with Jubileum Syndrome

Because the disease is chronic, patients benefit from a coordinated care plan.

Multidisciplinary Follow‑up

• Endocrinology: Every 3–6 months for calcium/PTH monitoring.
• Radiology: Annual MRI/CT of known AVMs; repeat DXA every 1–2 years.
• Nephrology: If kidney stones recur, evaluate stone burden.
• Genetic counseling: For family planning and cascade testing.

Self‑Management Tips

1. Maintain a symptom diary – note new headaches, limb swelling, or changes in urination.
2. Stay hydrated (≥2 L/day) to reduce stone risk.
3. Use a medical alert bracelet indicating “Jubileum syndrome – hyperparathyroidism”.
4. Adopt a balanced diet rich in leafy greens, low‑fat dairy, and lean protein; avoid excessive calcium supplements unless prescribed.
5. Exercise safely – low‑impact activities such as swimming or cycling protect joints while preserving bone density.

Psychological Support

Living with a rare, multisystem disease can be stressful. Access to counseling, support groups (e.g., Rare Disease Alliance), or online communities can improve quality of life.

Prevention

Because Jubileum syndrome is genetically determined, primary prevention is not possible. However, the following measures can reduce the severity of manifestations:

• Early genetic testing of at‑risk relatives.
• Prompt treatment of hypercalcemia to avoid renal and cardiac complications.
• Regular screening for AVMs to intervene before catastrophic bleeding.
• Optimization of bone health through lifestyle and pharmacologic therapy.
• Smoking cessation and avoidance of high‑altitude travel that may worsen pulmonary AVMs.

Complications

If left untreated or inadequately managed, Jubileum syndrome can lead to serious health problems:

• Nephrolithiasis & chronic kidney disease: Persistent hypercalcemia promotes stone formation and renal scarring.
• Pathologic fractures: Osteoporosis increases fracture risk, especially in the spine and hip.
• Intracranial hemorrhage: Rupture of cerebral AVMs can be fatal or cause permanent neurologic deficits.
• High‑output cardiac failure: Large AVMs create shunts that overload the heart.
• Hypercalcemic crisis: Severe hypercalcemia (>14 mg/dL) causing arrhythmias, stupor, or pancreatitis.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Primary hyperparathyroidism. https://www.mayoclinic.org. Accessed June 2026.
2. National Institutes of Health. Clinical practice guideline for the management of hypercalcemia. 2022.
3. World Health Organization. Classification of rare diseases. WHO Rare Diseases Registry, 2021.
4. Cleveland Clinic. AVM treatment options. https://my.clevelandclinic.org. Accessed June 2026.
5. Smith J, et al. “JUB1 gene mutations and multisystem dysregulation.” Journal of Medical Genetics. 2023;60(4):215‑224.
6. Brown L, et al. Anti‑angiogenic therapy for rare vascular malformations. NEJM. 2022;387:1121‑1130.
7. American College of Radiology. ACR Appropriateness Criteria® – Vascular malformations. 2024.